SAREPTA THERAPEUTICS, INC. Cash and Restricted Cash
SAREPTA THERAPEUTICS, INC. (SRPT) had Cash and Restricted Cash of $581.27 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $581.27M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $477.57M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $814.41M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $626.20M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $581.27M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $477.57M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $814.41M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $626.20M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $526.18M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $256.45M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $1.12B 10-Q · filed 2026-08-05 |
| 2024-09-30 | $213.43M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $399.20M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $442.87M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $444.01M 10-K · filed 2026-03-02 |
| 2023-09-30 | $561.08M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $870.95M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $890.69M 10-Q · filed 2024-05-01 |
| 2022-12-31 | $985.80M 10-K · filed 2025-02-28 |
| 2022-09-30 | $1.06B 10-Q · filed 2023-11-01 |
| 2022-06-30 | $887.06M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $1.24B 10-Q · filed 2023-05-02 |
| 2021-12-31 | $2.13B 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.61B 10-Q · filed 2022-11-02 |
| 2021-06-30 | $1.71B 10-Q · filed 2022-08-02 |
| 2021-03-31 | $1.49B 10-Q · filed 2022-05-04 |
| 2020-12-31 | $1.51B 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.48B 10-Q · filed 2021-11-03 |
| 2020-06-30 | $1.65B 10-Q · filed 2021-08-04 |
| 2020-03-31 | $1.77B 10-Q · filed 2021-05-05 |
| 2019-12-31 | $843.64M 10-K · filed 2022-03-01 |
| 2019-09-30 | $733.39M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $817.05M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $737.39M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $370.83M 10-K · filed 2021-03-01 |
| 2018-09-30 | $209.70M 10-Q · filed 2019-11-07 |
| 2018-06-30 | $410.38M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $557.37M 10-Q · filed 2019-05-08 |
| 2017-12-31 | $599.83M 10-K · filed 2020-02-26 |
| 2017-09-30 | $617.77M 10-Q · filed 2018-10-31 |
| 2017-06-30 | $168.48M 10-Q · filed 2018-08-08 |
| 2016-12-31 | $122.56M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |